Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases

J Thorac Oncol. 2019 Mar;14(3):e45-e48. doi: 10.1016/j.jtho.2018.11.031. Epub 2018 Dec 10.
No abstract available

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung / drug therapy
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / secondary
  • Aged
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Cell Transformation, Neoplastic / drug effects
  • Cell Transformation, Neoplastic / genetics
  • Cell Transformation, Neoplastic / pathology*
  • Drug Resistance, Neoplasm*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Lung Neoplasms / secondary
  • Mutation*
  • Prognosis
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Proto-Oncogene Proteins p21(ras) / genetics*
  • Small Cell Lung Carcinoma / drug therapy
  • Small Cell Lung Carcinoma / genetics
  • Small Cell Lung Carcinoma / pathology*

Substances

  • Antineoplastic Agents, Immunological
  • KRAS protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Proto-Oncogene Proteins p21(ras)